Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
23847studies shown
Showing 20,161-20,172 of 23,847
Drug study icon
CompletedNCT02189772

Safety and Tolerability Study of Metadoxine Extended Release (MDX) (Previously Known as MG01CI) in PI-ADHD Adolescent Subjects

This study exists to understand whether the medication Metadoxine is both safe enough and useful enough to take further. Researchers are trying to understand whether the medication Metadoxine can improve attention, thinking, or day-to-day functioning.

Multiple locations, including Haifa
ADHDDrugFrom 13 Years to 17 Years
Countries
Israel
Sponsor
Alcobra Ltd.
Condition
ADHD
Drug study icon
TerminatedNCT03325894

Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)

This study exists to understand how the medication SHP465 holds up over time after the earliest research stage. Researchers are trying to understand whether the medication SHP465 can improve attention, thinking, or day-to-day functioning.

Multiple locations, including Dothan
ADHDDrugFrom 4 Years to 12 Years
Countries
United States
Sponsor
Shire
Condition
ADHD
Drug study icon
CompletedNCT02466386

Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder

This study exists to understand how the medication SPD489 holds up over time after the earliest research stage. Researchers are trying to understand whether the medication SPD489 can improve attention, thinking, or day-to-day functioning.

Multiple locations, including Dothan
ADHDDrugFrom 4 Years to 5 Years
Countries
United States
Sponsor
Shire
Condition
ADHD
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.